This Under-The-Radar Biotech’s Only Drug Candidate Could Become “A Mega-Blockbuster”

2020-06-05 21_11_06-White Capsules on Yellow Background · Free Stock PhotoWhile buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for NASH, a severe form of non-alcoholic fatty liver disease, has posted impressive clinical trial results – and, if ultimately successful, “needs only to gobble up a small portion of the total NASH market to become a mega-blockbuster.” For more, CLICK HERE.

Read More

The Best Way To Play This – And Other – COVID-19 Biotech Stocks

2020-06-04 22_28_52-Crop chemist holding in hands molecule model · Free Stock PhotoThe biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that surge is sustainable or justified, and what the best way to play the stock (and its counterparts) may be. For more, CLICK HERE.

Read More

3 Stocks For “Explosive Upside Potential” As Focus Locks In On The Biotech Space

2020-05-31 22_01_34-Crop chemist pouring clear liquid into fragile glassware in science center · Fre“Understandably, investors have taken a more cautious approach when navigating the confused financial environment, but focus is locking in on the biotech sector as it has been able to withstand the COVID-19-induced pressure on the market,” notes the author of today’s article. She proceeds to highlight three “Strong Buy”-rated biotech stocks trading for less than $5 a share that, with upside potential in the 500% to 700% range based on analyst price targets, possess “explosive upside potential.” For more, CLICK HERE.

Read More

Seeking Better Valuations In Emerging Markets

2020-05-29 00_55_53-Macro Photography of Tree · Free Stock PhotoIn the current market environment, the author of today’s article notes that “As a stock picker, it’s important to find areas where the risk and reward proposition is more positive,” and advises that “One of the areas where this is best exhibited is with emerging markets.” He proceeds to highlight three emerging market stocks trading at big discounts based on a number of metrics. For these three stocks, CLICK HERE.

Read More

Why This Cancer-Fighting Biotech With A Unique Name And Focus Belongs On Your Radar

2020-05-27 22_49_43-Pink Ribbons on Pink Surface · Free Stock PhotoThe “sleeper” biotech highlighted in today’s article, a company with a unique name and focused on therapies for very rare, pediatric cancers, has a promising pipeline – including two drugs that could be approved in the next year. This, combined with the fact that its stock price has steadily increased since its IPO (despite getting caught up in the coronavirus market sell-off), leads the author to recommend investors keep this company on their radars for potential buy the dip opportunities. For the biotech stock in question, CLICK HERE.

Read More

Should Biotech Stocks Come With A Warning Label At Current Levels?

2020-05-24 19_36_46-Woman in Gray Sweater Wearing Blue Framed Eyeglasses · Free Stock PhotoBiotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however, pointing to “two very important names” in the aforementioned ETF that “are starting to break down.” For more, CLICK HERE.

Read More

2 Biotech Penny Stocks With “Strong Buy” Ratings And “Sky-Scraping Upside Potential”

2020-05-18 22_33_16-Silver Liberty in God We Trust 1978 Coin · Free Stock PhotoAnticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than $5 per share, are taking center stage.” As such, she proceeds to highlight two “Strong Buy” rated biotech penny stocks with “sky-scraping upside potential”. For more, CLICK HERE.

Read More

2 Of The Most Promising Stocks In The Young – But Rapidly Growing – Gene Editing Space

2020-05-16 22_17_46-WindowWhen it comes to the nascent – but rapidly growing – gene editing space, the author of today’s article notes that “sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish.” With the market for gene editing therapies expected to grow by over 18% annually, he highlights two of the most promising gene editing stocks for biotech investors to consider. For more, CLICK HERE.

Read More